Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxazosin
Drug ID BADD_D00718
Description Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Indications and Usage For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Marketing Status Prescription; Discontinued
ATC Code C02CA04
DrugBank ID DB00590
KEGG ID D07874
MeSH ID D017292
PubChem ID 3157
TTD Drug ID D03MIR
NDC Product Code 0049-2614; 23155-092; 68071-4272; 50090-3927; 42291-259; 70518-2183; 68071-4892; 16729-415; 68382-784; 68788-7149; 70518-1560; 50090-0704; 0049-2040; 70518-1804; 70934-362; 68071-5153; 16729-414; 65427-018; 71610-043; 66267-377; 50090-5773; 70771-1112; 50090-0734; 0904-5523; 16729-213; 60505-0093; 68788-7328; 60505-0094; 68084-862; 43063-739; 59762-2420; 16729-211; 71335-0309; 23155-095; 63629-7891; 68382-785; 59762-2410; 50090-2153; 59762-2480; 71610-628; 68084-836; 71335-0002; 55154-7996; 0049-2410; 70934-921; 71610-153; 50090-0701; 23155-094; 68071-3298; 42291-258; 70771-1113; 0049-2512; 0904-5522; 68084-851; 50090-4000; 50090-4004; 23155-093; 42291-260; 60505-0096; 68382-786; 0904-5524; 50090-5540; 60505-0095; 50090-0706; 50090-3987; 68071-4273; 72189-117; 71610-160; 70934-366; 68382-783; 70771-1114; 70771-1115
Synonyms Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274
Chemical Information
Molecular Formula C23H25N5O5
CAS Registry Number 74191-85-8
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.002181%Not Available
Breast neoplasm16.10.02.001; 21.05.01.004--Not Available
Breast pain21.05.05.003--
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac arrest02.03.04.0010.000253%
Cardiac failure02.05.01.0010.000126%
Cardiomyopathy02.04.01.0010.000485%Not Available
Cataract06.06.01.0010.000969%
Cellulitis23.09.01.001; 11.02.01.0010.000969%Not Available
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Cerebrovascular disorder24.03.05.002; 17.08.02.002--Not Available
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.0190.000485%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.002665%Not Available
Chills15.05.03.016; 08.01.09.001--
Choking22.02.05.0010.000485%Not Available
Cholelithiasis09.03.01.002--Not Available
Cholestasis09.01.01.001--Not Available
Circulatory collapse24.06.02.0010.000727%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.000485%Not Available
Confusional state19.13.01.001; 17.02.03.0050.000969%
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.0010.001212%
Cough22.02.03.001--
Cystitis20.03.02.002; 11.01.14.001--
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 11 Pages